Limits...
Prognostic role of microRNA-205 in multiple human malignant neoplasms: a meta-analysis of 17 studies.

Zhang JY, Sun MY, Song NH, Deng ZL, Xue CY, Yang J - BMJ Open (2015)

Bottom Line: However, the results of different studies have been inconsistent.Our results indicate that elevated miRNA-205 was significantly associated with enhanced overall survival in the breast cancer subgroup (HR=0.78, 95% CI 0.67 to 0.91) and superior disease-free survival/recurrence-free survival in the adenocarcinoma subgroup (HR=0.68, 95% CI 0.49 to 0.94). miRNA-205 is a promising biomarker for predicting the recurrence and progression of patients with adenocarcinomas or breast cancer.Owing to its complex roles, further relevant studies are warranted.

View Article: PubMed Central - PubMed

Affiliation: From Department of Urology, The First Affiliated Hospital Of Nanjing Medical University, Nanjing, Jiangsu, China.

Show MeSH

Related in: MedlinePlus

Risk of bias summary. Review authors’ judgements for each risk of bias item for each included study.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4305071&req=5

BMJOPEN2014006244F3: Risk of bias summary. Review authors’ judgements for each risk of bias item for each included study.

Mentions: This meta-analysis was strictly performed according to the preferred reporting items of the systematic reviews and meta-analysis (PRISMA) statement.25 The key points of the quality assessment included clear definitions of the following: (1) the study population and country of origin, (2) the type of carcinoma, (3) the study design, (4) the outcome assessment, (5) the detection of miRNA-205, (5) the miRNA-205 cut-off value and (6) a sufficient follow-up period. Studies were excluded when they did not meet all of the above criteria, to maintain the quality of the meta-analysis. Sensitivity analyses were also performed to avoid biases in the results due to certain low-quality studies (figures 1A, B). Moreover, we used the Cochrane Risk of Bias tool and graded each potential source of bias as a low, high or unclear risk (http://www.cochrane-handbook.org; figures 2 and 3). A flow diagram with details of the study selection process is presented in figure 4.


Prognostic role of microRNA-205 in multiple human malignant neoplasms: a meta-analysis of 17 studies.

Zhang JY, Sun MY, Song NH, Deng ZL, Xue CY, Yang J - BMJ Open (2015)

Risk of bias summary. Review authors’ judgements for each risk of bias item for each included study.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4305071&req=5

BMJOPEN2014006244F3: Risk of bias summary. Review authors’ judgements for each risk of bias item for each included study.
Mentions: This meta-analysis was strictly performed according to the preferred reporting items of the systematic reviews and meta-analysis (PRISMA) statement.25 The key points of the quality assessment included clear definitions of the following: (1) the study population and country of origin, (2) the type of carcinoma, (3) the study design, (4) the outcome assessment, (5) the detection of miRNA-205, (5) the miRNA-205 cut-off value and (6) a sufficient follow-up period. Studies were excluded when they did not meet all of the above criteria, to maintain the quality of the meta-analysis. Sensitivity analyses were also performed to avoid biases in the results due to certain low-quality studies (figures 1A, B). Moreover, we used the Cochrane Risk of Bias tool and graded each potential source of bias as a low, high or unclear risk (http://www.cochrane-handbook.org; figures 2 and 3). A flow diagram with details of the study selection process is presented in figure 4.

Bottom Line: However, the results of different studies have been inconsistent.Our results indicate that elevated miRNA-205 was significantly associated with enhanced overall survival in the breast cancer subgroup (HR=0.78, 95% CI 0.67 to 0.91) and superior disease-free survival/recurrence-free survival in the adenocarcinoma subgroup (HR=0.68, 95% CI 0.49 to 0.94). miRNA-205 is a promising biomarker for predicting the recurrence and progression of patients with adenocarcinomas or breast cancer.Owing to its complex roles, further relevant studies are warranted.

View Article: PubMed Central - PubMed

Affiliation: From Department of Urology, The First Affiliated Hospital Of Nanjing Medical University, Nanjing, Jiangsu, China.

Show MeSH
Related in: MedlinePlus